Drugs / PEGLOXENATIDE
PEGLOXENATIDE
Trials 11 · a red edge is where a trial was stopped
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGLOXENATIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802213 ↗ |
| Known as | Peg-40 kd-loxenatide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802213 ↗ |
| Known as | PEGylated Loxenatide | “Evaluating PEGylated Loxenatide Injection（PEX168）in Monotherapy of Type 2 Diabetes Mellitus” NCT02477865 ↗ |
| Known as | PEX168 | “Polyethylene glycol loxenatide (PEX168) is a novel long-acting glucagon-like peptide-1 receptor agonist for T2DM.” PMID 31396983 ↗ Dec 2019 |
| Known as | Polyethylene Glycol Loxenatide | “Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).” NCT01976858 ↗3“Two specific GLP-1RAs are used in this study: semaglutide at 0.5 mg once weekly, or polyethylene glycol loxenatide at 0.2 mg once weekly.” NCT07558863 ↗ “Polyethylene glycol loxenatide (PEX168) is a novel long-acting glucagon-like peptide-1 receptor agonist for T2DM.” PMID 31396983 ↗ Dec 2019 “Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue” NCT01965509 ↗ |
| Modality | Peptide | “a new human glucagon-like peptide 1 (GLP-1) analogue” NCT01965496 ↗ |
| Route | Subcutaneous | “A injection administered subcutaneously” NCT01965496 ↗ |